Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021
Histogen Inc. (NASDAQ: HSTO) announced the upcoming release of its financial results for Q3 2021, scheduled for November 10, 2021, after market closure. The company specializes in developing first-in-class restorative therapeutics aimed at enhancing natural bodily repair processes. Utilizing hypoxia-induced multipotent cells, Histogen's technology platform addresses various therapeutic needs, including joint cartilage regeneration and soft tissue repair.
- None.
- None.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the third quarter will be released after the close of market on Wednesday, November 10, 2021.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications, including joint cartilage regeneration, spinal disk repair, tendon, ligament and other soft tissue repair. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
FAQ
When will Histogen Inc. release its Q3 2021 financial results?
What is the business focus of Histogen Inc.?
What are some therapeutic applications of Histogen's technology?
